HOME ·

ALPHAMAB-B

ALPHAMAB-B (09966.HK) JSKN021 bispecific ADC cleared by FDA for Phase I
Tags：
ALPHAMAB-B09966.HKNew Drug Update
2026-11-02
ALPHAMAB-B (09966.HK) JSKN033 doses first patient in Phase III cervical cancer study
Tags：
ALPHAMAB-B09966.HKClinical Trial
2026-10-28
ALPHAMAB-B (09966.HK): JSKN003 data at ESMO 2026, Cohort B ORR 100%, PROC median OS 23.5 months
Tags：
ALPHAMAB-B09966.HKNewTimeSpace
2026-10-26
ALPHAMAB-B (09966.HK): JSKN033 cervical cancer Phase I/II data at ESMO 2026, ORR 41.9%
Tags：
ALPHAMAB-B09966.HKNewTimeSpace
2026-10-26
ALPHAMAB-B (09966.HK): Anbenitamab Phase III data at ESMO 2026, first-line breast cancer risk cut 54%
Tags：
ALPHAMAB-B09966.HKoverseas
2026-10-26
ALPHAMAB-B (09966.HK): Exercises Warrant to Buy Pathos AI Preferred Shares for US$62.5m
Tags：
NewTimeSpaceALPHAMAB-B09966.HK
2026-10-23
ALPHAMAB-B (09966.HK): NDA for Anbenitamab Combination as First-Line Treatment for HER2-Positive Advanced Breast Cancer Accepted by NMPA
Tags：
ALPHAMAB-B09966.HKR&D Progress
2026-08-18
CSPC PHARMA(01093.HK): NDA for Neoadjuvant Therapy of Anitumab Combined with HB1801 in HER2‑positive Breast Cancer Accepted and Granted Priority Review
Tags：
CSPC PHARMA01093.HKALPHAMAB-BNew Drug Application
2026-08-04
ALPHAMAB-B(09966.HK): CDE Grants Approval for Phase III Clinical Trial of JSKN033 in Cervical Cancer
Tags：
ALPHAMAB-B09966.HKClinical Trial
2026-08-03